1. AIFA warns of risk of thrombotic events after abrupt discontinuation of anagrelide

   News item 05 March 2022 Pages: 1 - 1

2. Health Canada: risk of accidental poisoning from COVID-19 rapid antigen test kits

   News item 05 March 2022 Pages: 2 - 2

3. Recall of certain batches of fluorouracil injection by medac Pharma

   Media release 05 March 2022 Pages: 3 - 3

4. Screening for immunocompromise essential before Zostavax use

   News item 05 March 2022 Pages: 4 - 4

5. TGA warns against off-label use of SGLT-1 inhibitors for T1DM

   News item 05 March 2022 Pages: 5 - 5

6. Warning of ipilimumab-related retinal detachment

   News item 05 March 2022 Pages: 6 - 6

7. Antipsychotic use in pregnancy may increase risk of gestational diabetes

   Clinical study 05 March 2022 Pages: 7 - 7

8. Isotretinoin not associated with increased risk of adverse neuropsychiatric outcomes

   Clinical study 05 March 2022 Pages: 8 - 8

9. Low incidence of teicoplanin-related thrombocytopenia

   Clinical study 05 March 2022 Pages: 9 - 9

10. No increase in aortic aneurysm and dissection with fluoroquinolone use

    Clinical study 05 March 2022 Pages: 10 - 10

11. Risk of liver and kidney toxicity, hypersensitivity reactions with antisense oligonucleotides

    Clinical study 05 March 2022 Pages: 11 - 11

12. SGLT-2 inhibitors increase risk of Fournier's gangrene, especially in male patients

    Clinical study 05 March 2022 Pages: 12 - 12

13. Other adverse reaction research

    News item 05 March 2022 Pages: 13 - 13

14. Abatacept/hydroxychloroquine/prednisone

    Case report 05 March 2022 Pages: 14 - 14

15. Acenocoumarol/warfarin

    Case report 05 March 2022 Pages: 15 - 15

16. Acetazolamide

    Case report 05 March 2022 Pages: 16 - 16

17. Acetazolamide/mannitol

    Case report 05 March 2022 Pages: 17 - 17

18. Acitretin

    Case report 05 March 2022 Pages: 18 - 18

19. Adalimumab

    Case report 05 March 2022 Pages: 19 - 19

20. Adalimumab/etanercept

    Case report 05 March 2022 Pages: 20 - 20

21. Adalimumab/infliximab/vedolizumab

    Case report 05 March 2022 Pages: 21 - 21

22. Adalimumab/infliximab/vedolizumab

    Case report 05 March 2022 Pages: 22 - 22

23. Adalimumab/minocycline

    Case report 05 March 2022 Pages: 23 - 23

24. Adenosine

    Case report 05 March 2022 Pages: 24 - 24

25. Aflibercept

    Case report 05 March 2022 Pages: 25 - 25

26. Aflibercept/bevacizumab/triamcinolone

    Case report 05 March 2022 Pages: 26 - 26

27. Albumin-human/midodrine/octreotide

    Case report 05 March 2022 Pages: 27 - 27

28. Alemtuzumab

    Case report 05 March 2022 Pages: 28 - 28

29. Alemtuzumab/levothyroxine-sodium

    Case report 05 March 2022 Pages: 29 - 29

30. Allopurinol

    Case report 05 March 2022 Pages: 30 - 30

31. Allopurinol/plasma/rasburicase

    Case report 05 March 2022 Pages: 31 - 31

32. Amantadine/ropinirole

    Case report 05 March 2022 Pages: 32 - 32

33. Amikacin

    Case report 05 March 2022 Pages: 33 - 33

34. Amiodarone

    Case report 05 March 2022 Pages: 34 - 34

35. Amiodarone/lidocaine

    Case report 05 March 2022 Pages: 35 - 35

36. Amiodarone/metoprolol

    Case report 05 March 2022 Pages: 36 - 36

37. Amphotericin-b-liposomal

    Case report 05 March 2022 Pages: 37 - 37

38. Amphotericin-b-liposomal/isavuconazonium/micafungin

    Case report 05 March 2022 Pages: 38 - 38

39. Anakinra/hydroxychloroquine

    Case report 05 March 2022 Pages: 39 - 39

40. Anakinra/prednisone

    Case report 05 March 2022 Pages: 40 - 40

41. Anti-inflammatories

    Case report 05 March 2022 Pages: 41 - 41

42. Antibacterials

    Case report 05 March 2022 Pages: 42 - 42

43. Antibacterials

    Case report 05 March 2022 Pages: 43 - 43

44. Antihypertensive/berberine/momordica-charantia

    Case report 05 March 2022 Pages: 44 - 44

45. Antihypertensives

    Case report 05 March 2022 Pages: 45 - 45

46. Antineoplastics

    Case report 05 March 2022 Pages: 46 - 46

47. Antineoplastics

    Case report 05 March 2022 Pages: 47 - 47

48. Antineoplastics

    Case report 05 March 2022 Pages: 48 - 48

49. Antineoplastics

    Case report 05 March 2022 Pages: 49 - 49

50. Antineoplastics

    Case report 05 March 2022 Pages: 50 - 50